{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:43:28Z","timestamp":1777866208993,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K01AI125830"],"award-info":[{"award-number":["K01AI125830"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K01"],"award-info":[{"award-number":["K01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000711","name":"Society for Experimental Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.vaccine.2019.02.066","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T09:40:19Z","timestamp":1552297219000},"page":"2099-2105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of alternative endpoints for ZIKV vaccine efficacy trials"],"prefix":"10.1016","volume":"37","author":[{"given":"Rachel A.","family":"Mercaldo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Bellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.02.066_b0005","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1602113","article-title":"Zika virus","volume":"374","author":"Petersen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.066_b0010","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects \u2014 reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.066_b0015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.02.066_b0020","unstructured":"European Centre for Disease Prevention and Control. Rapid risk assessment: Zika virus infection outbreak, French Polynesia. ECDC; 2014. p. 1\u201312."},{"key":"10.1016\/j.vaccine.2019.02.066_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/1178122X17708993","article-title":"Is Zika virus an emerging TORCH agent? An invited commentary","author":"Mehrjardi","year":"2017","journal-title":"Virol Res Treat"},{"key":"10.1016\/j.vaccine.2019.02.066_b0030","unstructured":"Pan American Health Organization. Countries and territories with autochthonous transmission in the Americas reported in 2015\u20132017; 2018. p. 41696. <https:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=11603&Itemid=41696&lang=en>."},{"key":"10.1016\/j.vaccine.2019.02.066_b0035","unstructured":"World Health Organization. WHO Director-General summarizes the outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barr\u00e9 syndrome \u2013 WHO Statement; 2016."},{"key":"10.1016\/j.vaccine.2019.02.066_b0040","unstructured":"World Health Organization. Fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus \u2013 WHO Statement; 2016."},{"key":"10.1016\/j.vaccine.2019.02.066_b0045","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.02.066_b0050","first-page":"1","article-title":"Preliminary modeling results for Zika virus transmission in2017","author":"Asher","year":"2017","journal-title":"BioRxiv"},{"key":"10.1016\/j.vaccine.2019.02.066_b0055","unstructured":"World Health Organization. \u201cEfficacy trials of ZIKV Vaccines: endpoints, trial design, site selection\u201d \u2013 WHO Workshop Meeting Report. Geneva; 2017."},{"key":"10.1016\/j.vaccine.2019.02.066_b0060","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix448","article-title":"Zika virus infection in pregnancy: maternal, fetal, and neonatal considerations","author":"Zorrilla","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.066_b0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2017.02.005","article-title":"Prospects for a Zika virus vaccine","volume":"46","author":"Barouch","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.02.066_b0070","unstructured":"Centers for Disease Control. Testing guidance. CdcGov; 2018. <https:\/\/www.cdc.gov\/zika\/hc-providers\/testing-guidance.html>."},{"key":"10.1016\/j.vaccine.2019.02.066_b0075","unstructured":"Centers for Disease Control. Guidance for US Laboratories testing for Zika Virus infection; 2017. p. 1\u201316. <https:\/\/www.cdc.gov\/zika\/pdfs\/laboratory-guidance-zika.pdf>."},{"key":"10.1016\/j.vaccine.2019.02.066_b0080","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01972-17","article-title":"Diagnostic testing for Zika virus: a postoutbreak update","author":"Theel","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.02.066_b0085","doi-asserted-by":"crossref","unstructured":"R Core Team. R software. R Found Stat Comput; 2018. https:\/\/doi.org\/10.1007\/978-3-540-74686-7.","DOI":"10.1007\/978-3-540-74686-7"},{"key":"10.1016\/j.vaccine.2019.02.066_b0090","unstructured":"Andersen K. Zika case numbers from PAHO; 2018. <https:\/\/andersen-lab.com\/secrets\/data\/zika-paho-numbers\/>."},{"key":"10.1016\/j.vaccine.2019.02.066_b0095","doi-asserted-by":"crossref","unstructured":"Lessler J, Ott CT, Carcelen AC, Konikoff JM, Williamson J, Bi Q, et al. Times to Key events in the course of Zika infection and their implications for surveillance: a systematic review and pooled analysis. IGARSS 2014; 2016. https:\/\/doi.org\/10.1101\/041913.","DOI":"10.1101\/041913"},{"key":"10.1016\/j.vaccine.2019.02.066_b0100","doi-asserted-by":"crossref","DOI":"10.1175\/1520-0450(1978)017<0350:MFEWSF>2.0.CO;2","article-title":"Methods for estimating wind speed frequency distributions","author":"Justus","year":"1978","journal-title":"J Appl Meteorol"},{"key":"10.1016\/j.vaccine.2019.02.066_b0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/bmj.327.7412.434","article-title":"Extent of the problem","volume":"327","author":"Taylor","year":"2003","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.vaccine.2019.02.066_b0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.15585\/mmwr.mm6613e1","article-title":"Vital signs: update on Zika virus\u2013associated birth defects and evaluation of all U.S. infants with congenital Zika virus exposure \u2014 U.S. Zika pregnancy registry, 2016","volume":"66","author":"Reynolds","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.02.066_b0115","doi-asserted-by":"crossref","unstructured":"United Nation, Department of Economic and Social Affairs PD. Trends in contraceptive use Worldwide 2015; 2015. https:\/\/doi.org\/10.1016\/j.contraception.2012.08.029.","DOI":"10.1016\/j.contraception.2012.08.029"},{"key":"10.1016\/j.vaccine.2019.02.066_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piu069","article-title":"Mother-to-child transmission of cytomegalovirus and prevention of congenital infection","author":"Pass","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2019.02.066_b0125","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1093\/clinids\/7.Supplement_1.S164","article-title":"Delayed manifestations of congenital rubella","volume":"7","author":"Sever","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.066_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2017.01.020","article-title":"Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic","author":"Eppes","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2019.02.066_b0135","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6547e2","article-title":"Description of 13 infants born during october 2015\u2013january 2016 with congenital Zika virus infection without microcephaly at birth \u2014 Brazil","author":"van der Linden","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:13:20Z","timestamp":1777536800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19302737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":27,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0264410X19302737"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of alternative endpoints for ZIKV vaccine efficacy trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}